Friday, January 04, 2019 12:49:41 PM
In-following from you post that for reference I have copied at the end of this post, please see my reply here:
--
Incorrect JRMKE.
https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-reports-third-quarter-2018-financial-results
If you look properly at the 2018 third quarter results PR you will see,
"R&D Expenses: Research and development expenses were $13.6 million for the third quarter of 2018"
"G&A Expenses: General and administrative expenses were $4.1 million for the third quarter of 2018"
Thus adding up to 17.7 million for the third quarter, rounding up to 18 million, and so including higher expenses relating to the new clinical trials we are looking at about or more than 20 million cash burn per quarter.
A company's running costs are more than just its R&D Expenses, which it appears is the only number you are referring to with your "13M", for their quarterly burn.
Therefore the recent raise of 144 million will last them about 1 year and a couple months as I previously stated.
Please refrain from writing replies insinuating negligence on the part of others when you haven't looked at all the relevant numbers, which is indeed negligent on your part.
Thank you.
--
JRMKE
Friday, December 28, 2018 8:37:09 AM
FATE's cash burn rate is not 20M per quarter, it is 13M! Yes, the IND clearance for FT500 will increase their burn rate, but that will be mitigated by their recent HQ exapnsion (Summer 2018) and their ability to manufacture the IPSC cells in house. Their cash runaway should last them 3-4 quarters more than you state and their recent partnership with Ono will also save them desperately needed cash to get to commercialization. Will more capital raises be needed, between now and then--absolutely! However, posting a burn rate numbers that are off by almost 100% is negligent on your part.
Recent FATE News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:02:49 PM
- Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 01:01:04 PM
- Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program • GlobeNewswire Inc. • 05/09/2024 12:30:00 PM
- Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting • GlobeNewswire Inc. • 05/03/2024 08:30:00 PM
- Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting • GlobeNewswire Inc. • 04/22/2024 08:30:00 PM
- Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/02/2024 08:01:00 PM
- Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement • GlobeNewswire Inc. • 03/19/2024 12:44:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:24:31 PM
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/05/2024 09:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 06:29:13 PM
- Fate Therapeutics to Present at Upcoming March Investor Conferences • GlobeNewswire Inc. • 03/01/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2024 09:10:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:03:08 PM
- Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates • GlobeNewswire Inc. • 02/26/2024 09:01:00 PM
- Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 11:06:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:10:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:10:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:09:29 PM
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/02/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:01:19 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM